

Manuela Monti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10194600/publications.pdf>

Version: 2024-02-01

34
papers

763
citations

687363

13
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

983
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Treatment with the Radiolabelled Somatostatin Analog ^{177}Lu -DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2013, 97, 347-354. | 2.5 | 104 |
| 2 | ^{177}Lu -Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1845-1851. | 6.4 | 103 |
| 3 | Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ^{177}Lu -DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 490-499. | 6.4 | 95 |
| 4 | Peptide receptor radionuclide therapy with ^{177}Lu -DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ^{18}F -FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1040-1046. | 6.4 | 77 |
| 5 | Feasibility and utility of re-treatment with ^{177}Lu -DOTATATE in GEP-NENs relapsed after treatment with ^{90}Y -DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1955-1963. | 6.4 | 62 |
| 6 | Dosimetry and safety of ^{177}Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017. | 6.4 | 37 |
| 7 | Dosimetry of ^{177}Lu -PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol. <i>Molecules</i> , 2019, 24, 621. | 3.8 | 34 |
| 8 | Combined use of ^{177}Lu -DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267. | 6.4 | 29 |
| 9 | Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 449-457. | 0.9 | 27 |
| 10 | ^{177}Lu -PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160. | 6.4 | 20 |
| 11 | Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined ^{18}F Fluoroestradiol PET/CT and ^{18}F Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821. | 2.6 | 19 |
| 12 | Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <i>Radiation Oncology</i> , 2019, 14, 112. | 2.7 | 16 |
| 13 | Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and ^{18}F -FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 721-727. | 1.9 | 14 |
| 14 | Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 863-871. | 2.3 | 14 |
| 15 | Circulating androgen receptor gene amplification and resistance to ^{177}Lu -PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232. | 6.4 | 13 |
| 16 | ^{68}Ga -PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , 2020, 8, 536. | 3.2 | 11 |
| 17 | Hydroxychloroquine as Prophylaxis for COVID-19: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 605185. | 3.5 | 10 |
| 18 | Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. <i>OncoTargets and Therapy</i> , 2014, 7, 1919. | 2.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). <i>Supportive Care in Cancer</i> , 2017, 25, 111-117. | 2.2 | 8 |
| 20 | PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 689. | 1.6 | 7 |
| 21 | Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. <i>Molecules</i> , 2022, 27, 4143. | 3.8 | 7 |
| 22 | Doxorubicin, Paclitaxel and Gemcitabine: a Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer. <i>Journal of Chemotherapy</i> , 2003, 15, 488-494. | 1.5 | 6 |
| 23 | New requirements for phase I trials: a challenge for Italian clinical research. <i>Tumori</i> , 2018, 104, 15-21. | 1.1 | 5 |
| 24 | Docetaxel Followed by Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer: A Phase I Study. <i>Tumori</i> , 2002, 88, 99-103. | 1.1 | 4 |
| 25 | Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. <i>Lung Cancer</i> , 2005, 47, 261-267. | 2.0 | 4 |
| 26 | Clinical research and burnout syndrome in Italy - only a physicians' affair?. <i>Trials</i> , 2021, 22, 205. | 1.6 | 4 |
| 27 | A New Approach for a Safe and Reproducible Seeds Positioning for Diffusing Alpha-Emitters Radiation Therapy of Squamous Cell Skin Cancer: A Feasibility Study. <i>Cancers</i> , 2022, 14, 240. | 3.7 | 4 |
| 28 | How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool. <i>JCO Oncology Practice</i> , 2021, 17, e68-e76. | 2.9 | 3 |
| 29 | [18F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue. <i>Pharmaceuticals</i> , 2021, 14, 599. | 3.8 | 3 |
| 30 | Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3020-3020. | 1.6 | 3 |
| 31 | Theranostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, . | 0.7 | 2 |
| 32 | Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Tumore del Timo). <i>Journal of Thoracic Oncology</i> , 2022, 17, 1010-1018. | 1.5 | 2 |
| 33 | 111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 135-142. | 1.1 | 1 |
| 34 | A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 600-600. | 1.6 | 1 |